O 1 P E C

IFW

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with, sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 14, 2005.

Jane A. Walker

Date

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Peyman

Serial No.:

10/631,143

Filed:

July 31, 2003

Group Art Unit:

1615

Confirmation No.:

2223

Examiner:

Unknown

Title:

TREATMENT OF OCULAR DISEASE

Attorney Ref.:

PMAN-23

Cincinnati, Ohio 45202

June 14, 2005

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56 and means of complying therewith according to 37 C.F.R. §\$1.97 and 1.98, the references listed on the attached form PTO-1449 are called to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application.

The Examiner is urged to consider the cited references listed on the attached form PTO-1449, and to make an independent decision with respect to materiality.

Applicant does not believe there is any fee due with this submission.

Should any fees or surcharges be deemed necessary, Examiner has authorization to charge fees or credit any overpayment to Deposit Account No. 23-3000. The Examiner is invited to telephone the undersigned attorney if there are any questions or issues.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

Beverly A. Lyman, Ph.D

Reg. No. 41,961

2700 Carew Tower 441 Vine Street Cincinnati, OH 45202 513 241-2324 513 421-7269 (facsimile)

| SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF (MODIFIED) PATENT AND TRADES | | | | | | | | | PK PFICE PMAN/23 | | | | SRIAL NO. 10/631,143 | | |
|--|--|---|---|----------|---------------------|---------------------------------|----------|---------------------------------------|------------------|----------------------------|---------------|-----------|-------------------------|-------------------------------|--|
| | | | INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | | | | APPLICANT Gholam Peyman | | | | | |
| (37 CFR 1.98 | (Use several sheets if necessary) | | | | | 1 6 2005 | | FILING DATE July 31, 2003 | | | GROUP 1615 | | | | |
| | | | | _ | | U.S. F | PATERITA | DOOM ENTS | | | | | | | |
| EXAMINER INITIAL | | PA | TENT | NUMBE | R | ISSUE DATE | | PATENTEE | | CLASS | | SUBCLASS | | FILING DATE IF APPROPRIATE | |
| | A.A | | | | | | | | | | | | | | |
| | A.B | | | | | | | | | | | | | | |
| | A.C | | | | | | | | | | | | | | |
| | A.D | | | | | | _ | | | | | | | | |
| | A.E | | | | | | | | | | | | | | |
| | A.F | | | | | | | _ | | · | | | | | |
| | A.G | | | | | | | | | | | | | | |
| | A.H | | | | | | | | | | | | | | |
| | A.I | | | | | | | | | | | | | | |
| | A.J | | | | | | | | | | | | | | |
| | A.K | | | | | | L | | _ | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | PUBLICATION DATE | | | COUNTRY OR PATENT OFFICE | | | CLASS | SUBCLASS | | TRANSLATION (YES/NO) | |
| | A.L | | | | | | | | | | | | | | |
| | A.M | | | | | | | , , , , , , , , , , , , , , , , , , , | | | | | | | |
| | A.N | | | | | | | | | | | | | | |
| | A.O | | | - 11 | | | | | | | | | | | |
| | A.P | | | | | | | | | | | | | | |
| | A.Q | | | | | | | | | | | _ | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | | | | | | | | | |
| | A.R | Grisolano et al., Retinal Toxicity Study of Intravitreal Cyclosporin, Ophthalmic Surgery, March 1986, 17:155-156 | | | | | | | | | | | | | |
| | A.S | Kiryu et al., In Vivo Evaluation of the Inhibitory Effects of Tacrolimus (FK506) on Leukocyte Accumulation During Retinal Ischemia Reperfusion Injury, ARVO 1998 Meeting, Ft. Lauderdale, FL, Poster Presentation 1247-B128 | | | | | | | | | | | | | |
| | A.T Martin DF et al., Synergistic Effect of Rapamycin and Cyclosporin A in the Treatment of Experimental Autoimmune Uveoretinits, The Journal of Immunology, 1995, 154:922-927 | | | | | | | | | | | | | utoimmune | |
| EXAMINER | | | | | | | | DATE CONSIDERED | | | | | | | |
| EXAMINER: Include a cop | nitial if ci y of this f | tation co | nsider | ed, whet | her or | not in conform to applicant. | nance. [| Draw line throug | gh | citation | only if not i | n conform | nance <u>ar</u> | nd not considered. | |